Interleukin 13-mediated colitis in the absence of IL-4Rα signalling.

Sufficient evidence points to interleukin 13 (IL-13) as an important pathological factor in UC and raises hopes to a promising new treatment strategy.1–3 However, the outcomes of two recent clinical trials, both published in Gut 2015, suggest otherwise.4 ,5 A commentary published in the same issue d...

Full description

Bibliographic Details
Main Authors: Hoving, J, Cutler, A, Leeto, M, Horsnell, W, Dewals, B, Nieuwenhuizen, N, Brombacher, F
Format: Journal article
Language:English
Published: BMJ Publishing Group 2017
Description
Summary:Sufficient evidence points to interleukin 13 (IL-13) as an important pathological factor in UC and raises hopes to a promising new treatment strategy.1–3 However, the outcomes of two recent clinical trials, both published in Gut 2015, suggest otherwise.4 ,5 A commentary published in the same issue described these results as crushing the enthusiasm for anti-IL-13 treatment in UC.6 In this letter, we show evidence that the disease outcome is determined by the type of signalling pathway used by IL-13 in mice. Therefore, we suggest that directly blocking IL-13 remains a potential treatment strategy for a subset of patients with UC that have elevated tissue IL-13 production.